A phase-IB/II trial (NCT03260023) of an HPV16 E6/E7 and IL-2 vaccine (TG4001) plus a PD-L1 inhibitor in patients with R/M HPV16-positive cancers that did not respond to available standard treatments demonstrated an ORR of 23.5% [174]. This evidence concerns the gene CD274 and cancer.